Carrier C, Demoly P, Caimmi D
Unité d'allergologie, département de pneumologie et addictologie, hôpital Arnaud-de-Villeneuve, université de Montpellier, CHU de Montpellier, 371, avenue du Doyen-Gaston-Giraud, 34090 Montpellier, France.
Unité d'allergologie, département de pneumologie et addictologie, hôpital Arnaud-de-Villeneuve, université de Montpellier, CHU de Montpellier, 371, avenue du Doyen-Gaston-Giraud, 34090 Montpellier, France; Université Sorbonne, UPMC Paris 06, UMR-S 1136, IPLESP, équipe EPAR, 75013 Paris, France.
Rev Mal Respir. 2019 Feb;36(2):191-196. doi: 10.1016/j.rmr.2018.03.006. Epub 2018 Nov 3.
Several authors have proposed combined omalizumab and allergen immunotherapy (AIT) in patients suffering from severe allergic asthma to both increase disease control and decrease the severity through targeting the main allergen responsible for the respiratory symptoms.
In a female pediatric patient suffering from severe asthma, followed-up at the University Hospital of Montpellier (France), we prescribed an AIT to Alternaria after obtaining symptom control with omalizumab. The patient showed an overall improvement in symptoms after AIT was administered and the disease remained controlled long after cessation of omalizumab.
There are only a few publications evaluating the efficacy of the association of these two biotherapies in the management of severe allergic asthma. In addition there is, as yet, no common protocol for the administration of the two prescriptions. This approach to treatment would benefit from standardization in order to optimize the management of severe allergic asthma.
几位作者提出，对于患有严重过敏性哮喘的患者，联合使用奥马珠单抗和变应原免疫疗法（AIT），通过针对引发呼吸道症状的主要变应原，既能增强疾病控制，又能减轻疾病严重程度。
在法国蒙彼利埃大学医院接受随访的一名患有严重哮喘的儿科女性患者中，我们在使用奥马珠单抗控制症状后，为其开具了针对链格孢属的AIT。在给予AIT后，患者症状总体有所改善，并且在停用奥马珠单抗很长时间后疾病仍得到控制。
仅有少数出版物评估了这两种生物疗法联合用于治疗严重过敏性哮喘的疗效。此外，目前尚无这两种处方给药的通用方案。这种治疗方法将受益于标准化，以优化严重过敏性哮喘的管理。
